Gastrointestinal NeoplasmsNCT04361227
Utility of OverStitch Sx After ESD
An observational study of Gastrointestinal Neoplasms, run by Baylor College of Medicine at 1 site in United States.
Trial summary
This study is a prospective study where the investigators will make a database of all the patients who have received this procedure and will document various outcomes (i.e. number of sutures used, number of clips (if used), time required to close, complications/ issues). Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Gastrointestinal Neoplasms
- How many people
- 33 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jul 2020to 20 Oct 2022
- How long will I take part?
- 48 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients referred to/scheduled for ESD procedure at Baylor College of Medicine with possible mucosal defect closure.
Who may be able to join
- Adults age 18-99, who are scheduled to undergo ESD procedure with possible mucosal defect closure.
Who cannot join
- Age is less than 18 years old
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Study of Utility of OverStitch Sx Endoscopic Suturing System After ESD Procedure
This study is a prospective study where the investigators will make a database of all the patients who have received this procedure and will document various outcomes (i.e. number of sutures used, number of clips (if used), time required to close, complications/ issues). No changes will be done to the participant's procedure and the participants are asked to consent for the use of the participant's data in our database. The participants are being asked to be in this research study because the participants have been scheduled to undergo an ESD procedure at Baylor St. Luke Medical Center and will most likely require clipping and/or suturing following intervention. This study is important because this is a relatively new procedure; although it is a part of the participant's standard of care, it is not done in many hospitals. The investigators would like to document the outcomes and results of such procedures to continuously improve our standard of care.
Read the detailed description
Resection of gastrointestinal neoplastic lesions at an early stage has been associated with improved clinical outcomes. While surgery has been traditionally performed for the resection of these precancerous or cancerous lesions confined to the mucosa of the GI tract, it is often associated with a higher morbidity and mortality rate compared to alternative endoscopic therapies. Recently, endoscopic submucosal dissection (ESD) has emerged as a new endoscopic technique that allows en-bloc resection of GI lesions, irrespective of size. In comparison to other endoscopic techniques, such as endoscopic mucosal resection (EMR), ESD is associated with higher curative resection rates and lower recurrence. While ESD was initially developed for the treatment of gastric cancer in Asia, which is relatively rare in the West, this technique would intuitively seem suitable for the resection of other superficial neoplastic lesions in the GI tract (i.e. large colon polyps, Barrett's mucosa, early non-invasive cancer). With the differences in patient population and disease location one can anticipate some differences in outcomes between ESD performed in Asian and US patients. Endoscopic Submucosal Dissection (ESD) is considered the gold standard for removal of pre-cancerous lesions from the GI tract, as histological analysis is more definitive, and the recurrence rate is lower as compared to endoscopic mucosal resection (EMR).
While ESD is useful for therapeutic and diagnostic purposes, the technique is rather difficult and detailed requiring extended procedure times. The most common complications of the ESD techniques are bleeding and perforation. Other rare complications include aspiration pneumonia, air embolisms, or stenosis. For this reason, closure of the mucosa following an endoscopic resection became an area of increased interest.
A randomized study in October of 2019 examined if prophylactic closure of a mucosal defect with clips would reduce the risk of bleeding following endoscopic intervention by EMR. 919 patients were randomly assigned to groups with 3.5% of patients experiencing post-procedure bleeding compared to 7.1% within the control group. Through this randomized trial, they found a significant reduction in post-procedural bleeding when patients undergo endoscopic clip closure of the mucosal defect.
With the advancements in endoscopic therapy, post-procedural clipping is now a well-established means of treatment following mucosal resections. Clipping, however, has two limitations including their inability to close large defects and the increasing difficulty in removal of those clips. To address these issues, endoscopic suturing systems have been developed which simulate the effectiveness of surgical stitching. The OverStitch Sx (Apollo Endosurgery Inc.) is commercially available and widely used in various applications such as the fixation of esophageal stents, suturing of ulcers, or reduction of anastamoses in bariatric surgeries.
Kantsevoy et al. in a 2014 retrospective study has shown that large mucosal defects treated with endoscopic suturing following an ESD resulted in a decrease rate of adverse events as well as the need for hospitalizations. All patient lesions were successfully and completely closed with no delayed or immediate adverse events following the procedure. The study concludes that the use of the Overstitch Sx device is fast and feasible and can decrease treatment costs by reducing the need to hospitalize patients.
- Conditions
- Gastrointestinal Neoplasms
- Keywords
- Gastrointestinal Neoplasms, OverStitch Sx, Endoscopic Submucosal Dissection
- Medical subject headings
- Gastrointestinal Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical/technical success rate utilizing endosuture
To assess feasibility and technical success of using Overstitch Sx system for closure after ESD
Measured: 2 years
Rate of patients reported with bleeding/perforation post-ESD procedure
Conduct follow-ups for risk of bleeding and perforation after closure
Measured: 2 years
Closure time after ESD
Record time needed to close lesion
Measured: 2 years
Secondary outcomes (2)
Additional clip closure
Identify, if any, need for additional clipping after endoscopic suture closure
Measured: 2 years
Clips used post-ESD
Record number of sutures needed to close lesion
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2020
- Study start2 Jul 2020
- Primary completion31 May 2022
- Study completion20 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastrointestinal NeoplasmsStudies of the same condition, open and under way.
- More trials run by Baylor College of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 33 participants (actual)
- Target duration
- 48 Months
Sponsor and investigators
- Lead sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Othman, Baylor College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04361227
- Sponsor's protocol ID
- H-47184
- Status last verified
- Feb 2023
- First submitted
- 22 Apr 2020
- Last updated
- 15 Feb 2023
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided: Study is currently considered as a single-center prospective study.
Publications
Keihanian T, Zabad N, Khalaf M, Abdel-Jaber W, Kim YI, Jawaid SA, Abidi WM, Marginean EC, Othman MO. Safety and efficacy of a novel suturing device for closure of large defects after endoscopic submucosal dissection (with video). Gastrointest Endosc. 2023 Sep;98(3):381-391. doi: 10.1016/j.gie.2023.04.006. Epub 2023 Apr 14.
PubMed 37061137
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Study of Utility of OverStitch Sx Endoscopic Suturing System After ESD Procedure
- ClinicalTrials.gov ID
- NCT04361227
- Acronym / sponsor ID
- H-47184
- Conditions
- Gastrointestinal Neoplasms
- Keywords
- Gastrointestinal Neoplasms, OverStitch Sx, Endoscopic Submucosal Dissection
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 33 participants (actual)
- Lead sponsor
- Baylor College of MedicineUniversity, hospital or other
- Study start
- 2 Jul 2020 (actual)
- Primary completion
- 31 May 2022 (actual)
- Study completion
- 20 Oct 2022 (actual)
- First posted
- 24 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective study where the investigators will make a database of all the patients who have received this procedure and will document various outcomes (i.e. number of sutures used, number of clips (if used), time required to close, complications/ issues). No changes will be done to the participant's procedure and the participants are asked to consent for the use of the participant's data in our database. The participants are being asked to be in this research study because the participants have been scheduled to undergo an ESD procedure at Baylor St. Luke Medical Center and will most likely require clipping and/or suturing following intervention. This study is important because this is a relatively new procedure; although it is a part of the participant's standard of care, it is not done in many hospitals. The investigators would like to document the outcomes and results of such procedures to continuously improve our standard of care.
Detailed description
Resection of gastrointestinal neoplastic lesions at an early stage has been associated with improved clinical outcomes. While surgery has been traditionally performed for the resection of these precancerous or cancerous lesions confined to the mucosa of the GI tract, it is often associated with a higher morbidity and mortality rate compared to alternative endoscopic therapies. Recently, endoscopic submucosal dissection (ESD) has emerged as a new endoscopic technique that allows en-bloc resection of GI lesions, irrespective of size. In comparison to other endoscopic techniques, such as endoscopic mucosal resection (EMR), ESD is associated with higher curative resection rates and lower recurrence. While ESD was initially developed for the treatment of gastric cancer in Asia, which is relatively rare in the West, this technique would intuitively seem suitable for the resection of other superficial neoplastic lesions in the GI tract (i.e. large colon polyps, Barrett's mucosa, early non-invasive cancer). With the differences in patient population and disease location one can anticipate some differences in outcomes between ESD performed in Asian and US patients. Endoscopic Submucosal Dissection (ESD) is considered the gold standard for removal of pre-cancerous lesions from the GI tract, as histological analysis is more definitive, and the recurrence rate is lower as compared to endoscopic mucosal resection (EMR).
While ESD is useful for therapeutic and diagnostic purposes, the technique is rather difficult and detailed requiring extended procedure times. The most common complications of the ESD techniques are bleeding and perforation. Other rare complications include aspiration pneumonia, air embolisms, or stenosis. For this reason, closure of the mucosa following an endoscopic resection became an area of increased interest.
A randomized study in October of 2019 examined if prophylactic closure of a mucosal defect with clips would reduce the risk of bleeding following endoscopic intervention by EMR. 919 patients were randomly assigned to groups with 3.5% of patients experiencing post-procedure bleeding compared to 7.1% within the control group. Through this randomized trial, they found a significant reduction in post-procedural bleeding when patients undergo endoscopic clip closure of the mucosal defect.
With the advancements in endoscopic therapy, post-procedural clipping is now a well-established means of treatment following mucosal resections. Clipping, however, has two limitations including their inability to close large defects and the increasing difficulty in removal of those clips. To address these issues, endoscopic suturing systems have been developed which simulate the effectiveness of surgical stitching. The OverStitch Sx (Apollo Endosurgery Inc.) is commercially available and widely used in various applications such as the fixation of esophageal stents, suturing of ulcers, or reduction of anastamoses in bariatric surgeries.
Kantsevoy et al. in a 2014 retrospective study has shown that large mucosal defects treated with endoscopic suturing following an ESD resulted in a decrease rate of adverse events as well as the need for hospitalizations. All patient lesions were successfully and completely closed with no delayed or immediate adverse events following the procedure. The study concludes that the use of the Overstitch Sx device is fast and feasible and can decrease treatment costs by reducing the need to hospitalize patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 48 Months
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients referred to/scheduled for ESD procedure at Baylor College of Medicine with possible mucosal defect closure.
Key inclusion criteria (1 listed)
- Adults age 18-99, who are scheduled to undergo ESD procedure with possible mucosal defect closure.
Key exclusion criteria (1 listed)
- Age is less than 18 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Clinical/technical success rate utilizing endosuture
Time frame: 2 years
To assess feasibility and technical success of using Overstitch Sx system for closure after ESD
Rate of patients reported with bleeding/perforation post-ESD procedure
Time frame: 2 years
Conduct follow-ups for risk of bleeding and perforation after closure
Closure time after ESD
Time frame: 2 years
Record time needed to close lesion
2 secondary outcomes
Additional clip closure
Time frame: 2 years
Clips used post-ESD
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2023.
- Derived from this study: PubMed 37061137Keihanian T, Zabad N, Khalaf M, Abdel-Jaber W, Kim YI, Jawaid SA, Abidi WM, Marginean EC, Othman MO. Safety and efficacy of a novel suturing device for closure of large defects after endoscopic submucosal dissection (with video). Gastrointest Endosc. 2023 Sep;98(3):381-391. doi: 10.1016/j.gie.2023.04.006. Epub 2023 Apr 14.
- Individual participant dataSharing planned: Undecided. Study is currently considered as a single-center prospective study.
Related trials for Gastrointestinal Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastrointestinal Neoplasms, run by Baylor College of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical/technical success rate utilizing endosuture (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04361227, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2023.